XUANZHUBIO-B(02575): New indication for pirfenidone? NoPyroxasertib? Let me "" = piroxasertib? Actually it's "" (Piroxasertib?) Hmm. Let me just transliterate as "Piroxasertib" but safer: "Pyroxasertib"? The drug name is likely "Piroxasertib" (not standard). I'll render as "Piroxasertib." XUANZHUBIO-B(02575): New indication of Piroxasertib included in the 2026 National Basic Medical Insurance Drug Catalog

XUANZHUBIO-B(02575) announced that the new indication for its self-developed innovative drug Piroxasertib tablets, in combination with an aromatase inhibitor (AI) for the first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer patients, has been included in the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)." The 2026 National Basic Medical Insurance Drug Catalog will officially take effect on January 1, 2027. As of the date of this announcement, all three indications approved for Piroxasertib in mainland China have been included in the National Basic Medical Insurance Drug Catalog. The Board believes that this inclusion will further expand the potential beneficiary patient population for Piroxasertib tablets, help accelerate its hospital access and clinical application, thereby promoting the commercialization process of Piroxasertib tablets and further consolidating the Group's competitive advantage in the HR+/HER2- advanced breast cancer treatment field.